These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 32203221)

  • 1. OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody.
    Ohmura H; Yamaguchi K; Hanamura F; Ito M; Makiyama A; Uchino K; Shimokawa H; Tamura S; Esaki T; Mitsugi K; Shibata Y; Oda H; Tsuchihashi K; Ariyama H; Kusaba H; Oda Y; Akashi K; Baba E
    Br J Cancer; 2020 May; 122(10):1507-1517. PubMed ID: 32203221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of central/effector memory T cells and T-helper 1 polarization in malignant melanoma patients treated with anti-programmed death-1 antibody.
    Yamaguchi K; Mishima K; Ohmura H; Hanamura F; Ito M; Nakano M; Tsuchihashi K; Ota SI; Wada N; Uchi H; Ariyama H; Kusaba H; Niiro H; Akashi K; Baba E
    Cancer Sci; 2018 Oct; 109(10):3032-3042. PubMed ID: 30066977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of PD-1 blockade in cervical cancer is related to a CD8
    Heeren AM; Rotman J; Stam AGM; Pocorni N; Gassama AA; Samuels S; Bleeker MCG; Mom CH; Zijlmans HJMAA; Kenter GG; Jordanova ES; de Gruijl TD
    J Immunother Cancer; 2019 Feb; 7(1):43. PubMed ID: 30755279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment.
    Macek Jilkova Z; Aspord C; Kurma K; Granon A; Sengel C; Sturm N; Marche PN; Decaens T
    Clin Transl Gastroenterol; 2019 Jul; 10(7):e00058. PubMed ID: 31295151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
    Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
    Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LAG3 and PD1 Regulate CD8+ T Cell in Diffuse Large B-cell Lymphoma Patients.
    Liu Y; Guo X; Zhan L; Wang L; Wang X; Jiang M
    Comput Math Methods Med; 2021; 2021():4468140. PubMed ID: 34422089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The tissue-resident marker CD103 on peripheral blood T cells predicts responses to anti-PD-1 therapy in gastric cancer.
    Nose Y; Saito T; Yamamoto K; Yamashita K; Tanaka K; Yamamoto K; Makino T; Takahashi T; Kawashima A; Haruna M; Hirata M; Ueyama A; Iwahori K; Satoh T; Kurokawa Y; Eguchi H; Doki Y; Wada H
    Cancer Immunol Immunother; 2023 Jan; 72(1):169-181. PubMed ID: 35776160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8
    Tada Y; Togashi Y; Kotani D; Kuwata T; Sato E; Kawazoe A; Doi T; Wada H; Nishikawa H; Shitara K
    J Immunother Cancer; 2018 Oct; 6(1):106. PubMed ID: 30314524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.
    Sangro B; Melero I; Wadhawan S; Finn RS; Abou-Alfa GK; Cheng AL; Yau T; Furuse J; Park JW; Boyd Z; Tang HT; Shen Y; Tschaika M; Neely J; El-Khoueiry A
    J Hepatol; 2020 Dec; 73(6):1460-1469. PubMed ID: 32710922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1
    Kamada T; Togashi Y; Tay C; Ha D; Sasaki A; Nakamura Y; Sato E; Fukuoka S; Tada Y; Tanaka A; Morikawa H; Kawazoe A; Kinoshita T; Shitara K; Sakaguchi S; Nishikawa H
    Proc Natl Acad Sci U S A; 2019 May; 116(20):9999-10008. PubMed ID: 31028147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy.
    Reschke R; Gussek P; Boldt A; Sack U; Köhl U; Lordick F; Gora T; Kreuz M; Reiche K; Simon JC; Ziemer M; Kunz M
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the immune cell population in peripheral blood on response and survival in patients receiving neoadjuvant chemotherapy for advanced gastric cancer.
    He Q; Li G; Ji X; Ma L; Wang X; Li Y; Fan C
    Tumour Biol; 2017 May; 39(5):1010428317697571. PubMed ID: 28475005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased LAG3 expression on T effector cells and regulatory T cells in SAA.
    Sun Y; Liu C; Jiao T; Xie N; Wang H; Qi W; Shao Z
    Int J Hematol; 2020 Dec; 112(6):757-763. PubMed ID: 32785818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of the immune checkpoint receptors PD-1, LAG3, and TIM3 in the immune context of stage II and III gastric cancer by using single and chromogenic multiplex immunohistochemistry.
    Park Y; Seo AN; Koh J; Nam SK; Kwak Y; Ahn SH; Park DJ; Kim HH; Lee HS
    Oncoimmunology; 2021; 10(1):1954761. PubMed ID: 34367732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma.
    Kubo Y; Fukushima S; Inamori Y; Tsuruta M; Egashira S; Yamada-Kanazawa S; Nakahara S; Tokuzumi A; Miyashita A; Aoi J; Kajihara I; Tomita Y; Wakamatsu K; Jinnin M; Ihn H
    J Dermatol Sci; 2019 Jan; 93(1):33-40. PubMed ID: 30318169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IFN-γ down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer.
    Ding G; Shen T; Yan C; Zhang M; Wu Z; Cao L
    BMC Cancer; 2019 Nov; 19(1):1053. PubMed ID: 31694582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed death (PD)-1 molecule and its ligand PD-L1 distribution among memory CD4 and CD8 T cell subsets in human immunodeficiency virus-1-infected individuals.
    Rosignoli G; Lim CH; Bower M; Gotch F; Imami N
    Clin Exp Immunol; 2009 Jul; 157(1):90-7. PubMed ID: 19659774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Expression Level of PD1 by Tumor-Infiltrating CD8
    Kim HD; Song GW; Park S; Jung MK; Kim MH; Kang HJ; Yoo C; Yi K; Kim KH; Eo S; Moon DB; Hong SM; Ju YS; Shin EC; Hwang S; Park SH
    Gastroenterology; 2018 Dec; 155(6):1936-1950.e17. PubMed ID: 30145359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.